



IPW

PATENT
Customer No. 22,852
Attorney Docket No. 9914.0004-00

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)
)
Mary Jane Cardosa et al.) Group Art Unit: 1648
)
Application No.: 10/786,380) Examiner: M. MOSHER
)
Filed: February 24, 2004) Confirmation No.: 3579
)
For: RECOMBINANT MVA VIRUS EXPRESSING DENGUE VIRUS
ANTIGENS AND THE USE THEREOF IN VACCINES

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

TRANSMITTAL LETTER

Enclosed is a reply to the Office Action of September 21, 2006. The items
checked below are appropriate:

- ☒ Applicants enclose an Amendment and Response (8 pages). The claims are
calculated below:

	Claims Remaining After Amendment		Highest Number Previously Paid	Present Extra	Rate	Additional Fee
Total	13	-	39	0	x \$ 50	\$ -0-
Indep.	1	-	3	0	x \$200	-0-
<input type="checkbox"/> First Presentation of Multiple Dep. Claim(s)					+\$360	-0-
Subtotal						\$ -0-
Reduction by ½ if small entity						- -0-
TOTAL						\$ -0-

- ☒ No additional claims fee is required.

Please grant any extensions of time required to enter this response and charge any additional required fees to our deposit account 06-0916.

Respectfully submitted,

Dated: December 14, 2006

By: _____


Salvatore J. Arrigo

Reg. No. 46,063

Telephone : 202-408-4160

Facsimile: 202-408-4160

E-mail: arrigos@finnegan.com



PATENT
Customer No. 22,852
Attorney Docket No. 9914.0004-00

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)
)
Mary Jane Cardoso et al.) Group Art Unit: 1648
)
Application No.: 10/786,380) Examiner: M. MOSHER
)
Filed: February 24, 2004) Confirmation No.: 3579
)
For: RECOMBINANT MVA VIRUS EXPRESSING DENGUE VIRUS
ANTIGENS AND THE USE THEREOF IN VACCINES

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

AMENDMENT AND RESPONSE

In response to the Office Action dated September 21, 2006, applicants submit
the following amendments and remarks.

Please amend the above-identified patent application as follows:

Amendments to the Specification are included in this paper.

Amendments to the Claims are reflected in the listing of claims in this paper.

Remarks begin on page 5 of this paper.